Site Editor

Sandy Srinivas, MD


Paul L. Nguyen, MD, on Salvage Radiotherapy, GnRH Agonist, Abiraterone, Prednisone, and Apalutamide in Prostate Cancer Treatment

Posted: Wednesday, March 8, 2023

Paul L. Nguyen, MD, of Dana-Farber Cancer Institute and Harvard Medical School, discusses the clinical implications of findings from the FORMULA-509 study, which suggest that, adding acetate/prednisone and apalutamide to salvage radiotherapy, plus 6 months of androgen-deprivation therapy, may improve outcomes, particularly in the subgroup of patients with a prostate-specific antigen level higher than 0.5 ng/mL.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.